Olema Pharmaceuticals (OLMA) News Today $8.28 -0.44 (-5.05%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Victory Capital Management Inc. Has $10.17 Million Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Victory Capital Management Inc. raised its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 9.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 851,512 shares of the company's stock after buying anNovember 21 at 3:18 AM | marketbeat.comFY2025 Earnings Estimate for OLMA Issued By Lifesci CapitalOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Investment analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Olema Pharmaceuticals in a research note issued on Wednesday, November 13th. Lifesci Capital analyst S. Slutsky anticipates that the company will pNovember 15, 2024 | marketbeat.comHC Wainwright Has Pessimistic View of OLMA FY2024 EarningsOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Stock analysts at HC Wainwright dropped their FY2024 EPS estimates for Olema Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($2.34) per shNovember 15, 2024 | marketbeat.comPromising Developments and Strategic Collaborations Bolster Buy Rating for Olema PharmaceuticalsNovember 14, 2024 | markets.businessinsider.comOptimistic Outlook for Olema Pharmaceuticals: Promising Clinical Data and Strategic Pipeline DevelopmentsNovember 14, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)November 12, 2024 | markets.businessinsider.comOlema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12, 2024 | globenewswire.comOlema Oncology to Participate in Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 4, 2024 | globenewswire.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of "Buy" by BrokeragesShares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have been assigned a consensus rating of "Buy" from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average tweNovember 2, 2024 | marketbeat.comPromising Potential of Olema Pharmaceuticals’ Palazestrant and KAT6 Inhibitor Fuels Buy RatingOctober 26, 2024 | markets.businessinsider.comOlema Pharmaceuticals’ Promising KAT6 Inhibitor Program Justifies Buy RecommendationOctober 25, 2024 | markets.businessinsider.comOlema Pharmaceuticals' (OLMA) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Thursday.October 24, 2024 | marketbeat.comBuy Rating for Olema Pharmaceuticals: Promising Preclinical Data and Strategic Pipeline SynergyOctober 23, 2024 | markets.businessinsider.comOlema Oncology presents preclinical data on anti-tumor activity for OP-3136October 23, 2024 | markets.businessinsider.comOlema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024October 23, 2024 | globenewswire.comRenaissance Technologies LLC Makes New $576,000 Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Renaissance Technologies LLC purchased a new position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 53,200 shares of the company's stock, valued at approOctober 10, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comOlema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsOctober 9, 2024 | globenewswire.comPoint72 Asset Management L.P. Invests $34.75 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Point72 Asset Management L.P. bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,211,927 shares of the company's stock, valued at approximately $October 9, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of "Buy" by AnalystsShares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have received an average recommendation of "Buy" from the six ratings firms that are covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target pricOctober 8, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Dimensional Fund Advisors LPDimensional Fund Advisors LP cut its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 13.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,684,924 shares of the company's stocOctober 5, 2024 | marketbeat.com74,657 Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Acquired by Dana Investment Advisors Inc.Dana Investment Advisors Inc. acquired a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 74,657 shares of the company's stock, valOctober 4, 2024 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2024 | globenewswire.comOlema Pharmaceuticals (NASDAQ:OLMA) Trading Down 3.8%Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 3.8%October 2, 2024 | marketbeat.comAffinity Asset Advisors LLC Purchases Shares of 275,000 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Affinity Asset Advisors LLC acquired a new position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 275,000 shares of the company's stock, valuSeptember 25, 2024 | marketbeat.comGreat Point Partners LLC Takes Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Great Point Partners LLC bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 796,880 shares of the company's stock, valued at approximately $8,622,000.September 24, 2024 | marketbeat.comBank of New York Mellon Corp Acquires 58,622 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Bank of New York Mellon Corp boosted its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 72.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 139,923 shares of the company's stock after buying an additional 58,62September 19, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Victory Capital Management Inc.Victory Capital Management Inc. boosted its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 26.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 774,792 shares of the comSeptember 16, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of "Buy" from AnalystsOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) has received a consensus rating of "Buy" from the six research firms that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price targeSeptember 13, 2024 | marketbeat.comCandriam S.C.A. Has $11.45 Million Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Candriam S.C.A. lifted its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 199.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,058,673 shares of the company's stock afteSeptember 9, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Trading 6.8% Higher Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.8%September 5, 2024 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2024 | globenewswire.comOlema Pharmaceuticals (NASDAQ:OLMA) Trading 3.7% Higher Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 3.7%August 23, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 4%Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 4%August 22, 2024 | marketbeat.comOlema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 21, 2024 | globenewswire.comHennion & Walsh Asset Management Inc. Makes New $945,000 Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Hennion & Walsh Asset Management Inc. bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 87,312 shares of the company's stoAugust 21, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of "Buy" by AnalystsOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) has been given an average rating of "Buy" by the six brokerages that are covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issueAugust 19, 2024 | marketbeat.comQ3 2024 EPS Estimates for Olema Pharmaceuticals, Inc. Raised by Capital One Financial (NASDAQ:OLMA)Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Capital One Financial lifted their Q3 2024 earnings estimates for Olema Pharmaceuticals in a note issued to investors on Wednesday, August 7th. Capital One Financial analyst N. Quibria now forecasts that the company will post earnings perAugust 12, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Vanguard Group Inc.Vanguard Group Inc. decreased its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 11.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,407,688 shares of the company's stockAugust 10, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Forecasted to Post FY2028 Earnings of $3.09 Per ShareOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Equities researchers at Capital One Financial decreased their FY2028 EPS estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 7th. Capital One Financial analyst N. QuibriaAugust 9, 2024 | marketbeat.comJPMorgan Chase & Co. Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $31.00JPMorgan Chase & Co. reduced their target price on Olema Pharmaceuticals from $33.00 to $31.00 and set an "overweight" rating for the company in a report on Thursday.August 8, 2024 | marketbeat.comBuy Rating for Olema Pharmaceuticals Based on Promising Clinical Data and Strategic Drug PositioningAugust 7, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)August 7, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Olema Pharmaceuticals (NASDAQ:OLMA)HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a research report on Wednesday.August 7, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 7.5%Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 7.5%August 7, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Posts Quarterly Earnings Results, Hits ExpectationsOlema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.54) earnings per share for the quarter, meeting the consensus estimate of ($0.54).August 7, 2024 | marketbeat.comInsider Selling: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Sells 2,400,000 Shares of StockAugust 7, 2024 | insidertrades.comBuy Rating Affirmed: Promising Clinical Trial Results and Future Prospects for Olema PharmaceuticalsAugust 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Olema Pharmaceuticals Amidst Promising Clinical Developments and Strategic CollaborationsAugust 7, 2024 | markets.businessinsider.com Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here OLMA Media Mentions By Week OLMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OLMA News Sentiment▼0.060.46▲Average Medical News Sentiment OLMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OLMA Articles This Week▼113▲OLMA Articles Average Week Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SUPN News CNTA News MNKD News GPCR News HRMY News EVO News IRON News GLPG News XNCR News NRIX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OLMA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
